Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
29
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Wagner Kristie Ann | VP, Principal Fin & Acct Off | 3 | $0 | $0 | 2022-07-11 |
| Triola Anna Diaz | Chief Commercial Officer | 4 | $0 | $0 | 2022-07-11 |
| Innoviva Strategic Opportunities LLC | Director, 10% Owner | 6 | $67.47M | $0 | 2022-07-11 |
| Ronsheim Matthew | See Remarks | 13 | $0 | $12.0K | 2022-07-11 |
| Altarac David | Chief Medical Officer | 13 | $0 | $12.0K | 2022-07-11 |
| Mueller John Patrick | Chief Development Officer | 22 | $0 | $12.8K | 2022-07-11 |
| Berger Heather A. | Director | 13 | $0 | $0 | 2022-07-11 |
| Perros Manoussos | See Remarks | 22 | $0 | $38.2K | 2022-07-11 |
| Tommasi Ruben | Chief Scientific Officer | 24 | $0 | $0 | 2022-07-11 |
| Mayer Howard | Director | 10 | $0 | $0 | 2022-07-11 |
| Keiley Elizabeth M | General Counsel | 12 | $0 | $12.0K | 2022-07-11 |
| Meek David D. | Director | 13 | $0 | $0 | 2022-07-11 |
| HASTINGS DAVID C | Director | 15 | $0 | $0 | 2022-07-11 |
| Gutch Michael | See Remarks | 14 | $0 | $12.0K | 2022-01-18 |
| Innoviva, Inc. | 10% Owner | 6 | $103.36M | $0 | 2021-05-03 |
| Kimble Eric Wilson | Chief Commercial Officer | 1 | $0 | $0 | 2020-01-23 |
| FHM LIFE SCIENCES VIII, L.P. | 10% Owner | 1 | $0 | $250.0K | 2020-01-09 |
| Preston Heather | Director, 10% Owner | 6 | $5.07M | $0 | 2019-06-19 |
| Norden Gregory | Director | 2 | $0 | $0 | 2019-06-19 |
| GALAKATOS NICHOLAS | Director, 10% Owner | 9 | $6.80M | $0 | 2019-06-19 |
| Isaacs Robin | Chief Medical Officer | 2 | $0 | $0 | 2019-01-18 |
| Topper James N | Director, 10% Owner | 8 | $5.64M | $0 | 2019-01-18 |
| ASTRAZENECA PLC | 10% Owner | 3 | $3.70M | $0 | 2018-09-28 |
| BONDERMAN DAVID | 10% Owner | 4 | $3.94M | $0 | 2018-09-28 |
| Pivotal bioVenture Partners Fund I U.G.P., Ltd | 10% Owner | 5 | $5.07M | $0 | 2018-09-28 |
| Clarus Ventures III, LLC | 10% Owner | 7 | $6.80M | $0 | 2018-09-28 |
| Novo Holdings A/S | 10% Owner | 4 | $16.35M | $0 | 2018-09-28 |
| Heron Patrick J | 10% Owner | 7 | $5.64M | $0 | 2018-09-28 |
| POWELL MICHAEL | 10% Owner | 5 | $5.07M | $0 | 2018-09-28 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Altarac David | Chief Medical Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 92,307 | — | $0 | 0 | SEC↗ |
| Altarac David | Chief Medical Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 50,000 | — | $0 | 0 | SEC↗ |
| Berger Heather A. | Director | J Other deriv | 2022-07-11 | 2022-07-11 | 11,000 | — | $0 | 0 | SEC↗ |
| Berger Heather A. | Director | J Other deriv | 2022-07-11 | 2022-07-11 | 17,307 | — | $0 | 0 | SEC↗ |
| HASTINGS DAVID C | Director | J Other deriv | 2022-07-11 | 2022-07-11 | 11,000 | — | $0 | 0 | SEC↗ |
| HASTINGS DAVID C | Director | J Other deriv | 2022-07-11 | 2022-07-11 | 26,583 | — | $0 | 0 | SEC↗ |
| Keiley Elizabeth M | General Counsel | J Other deriv | 2022-07-11 | 2022-07-11 | 20,833 | — | $0 | 0 | SEC↗ |
| Keiley Elizabeth M | General Counsel | J Other deriv | 2022-07-11 | 2022-07-11 | 50,000 | — | $0 | 0 | SEC↗ |
| Mayer Howard | Director | J Other deriv | 2022-07-11 | 2022-07-11 | 11,000 | — | $0 | 0 | SEC↗ |
| Mayer Howard | Director | J Other deriv | 2022-07-11 | 2022-07-11 | 12,500 | — | $0 | 0 | SEC↗ |
| Meek David D. | Director | J Other deriv | 2022-07-11 | 2022-07-11 | 11,000 | — | $0 | 0 | SEC↗ |
| Meek David D. | Director | J Other deriv | 2022-07-11 | 2022-07-11 | 17,307 | — | $0 | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 18,253 | — | $0 | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 25,092 | — | $0 | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 50,000 | — | $0 | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 75,698 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | J Other deriv | 2022-07-11 | 2022-07-11 | 183,013 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | J Other deriv | 2022-07-11 | 2022-07-11 | 69,970 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | J Other deriv | 2022-07-11 | 2022-07-11 | 325,755 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | J Other deriv | 2022-07-11 | 2022-07-11 | 145,000 | — | $0 | 0 | SEC↗ |
| Ronsheim Matthew | Chief of Pharma Sciences & M | J Other deriv | 2022-07-11 | 2022-07-11 | 20,000 | — | $0 | 0 | SEC↗ |
| Ronsheim Matthew | Chief of Pharma Sciences & M | J Other deriv | 2022-07-11 | 2022-07-11 | 33,333 | — | $0 | 0 | SEC↗ |
| Ronsheim Matthew | Chief of Pharma Sciences & M | J Other deriv | 2022-07-11 | 2022-07-11 | 15,000 | — | $0 | 0 | SEC↗ |
| Ronsheim Matthew | Chief of Pharma Sciences & M | J Other deriv | 2022-07-11 | 2022-07-11 | 20,000 | — | $0 | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 98,700 | — | $0 | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 6,465 | — | $0 | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 24,858 | — | $0 | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 50,000 | — | $0 | 0 | SEC↗ |
| Triola Anna Diaz | Chief Commercial Officer | J Other deriv | 2022-07-11 | 2022-07-11 | 100,000 | — | $0 | 0 | SEC↗ |
| Wagner Kristie Ann | VP, Principal Fin & Acct Off | J Other deriv | 2022-07-11 | 2022-07-11 | 73,400 | — | $0 | 0 | SEC↗ |
| Altarac David | Chief Medical Officer | D To issuer | 2022-07-11 | 2022-07-11 | 150,000 | — | $0 | 0 | SEC↗ |
| Berger Heather A. | Director | D To issuer | 2022-07-11 | 2022-07-11 | 27,500 | $2.20 | $60.5K | 0 | SEC↗ |
| HASTINGS DAVID C | Director | D To issuer | 2022-07-11 | 2022-07-11 | 27,500 | $2.20 | $60.5K | 0 | SEC↗ |
| Keiley Elizabeth M | General Counsel | D To issuer | 2022-07-11 | 2022-07-11 | 150,000 | — | $0 | 0 | SEC↗ |
| Mayer Howard | Director | D To issuer | 2022-07-11 | 2022-07-11 | 27,500 | $2.20 | $60.5K | 0 | SEC↗ |
| Meek David D. | Director | D To issuer | 2022-07-11 | 2022-07-11 | 27,500 | $2.20 | $60.5K | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | D To issuer | 2022-07-11 | 2022-07-11 | 150,000 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | D To issuer | 2022-07-11 | 2022-07-11 | 478,500 | — | $0 | 0 | SEC↗ |
| Ronsheim Matthew | Chief of Pharma Sciences & M | D To issuer | 2022-07-11 | 2022-07-11 | 150,000 | — | $0 | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | D To issuer | 2022-07-11 | 2022-07-11 | 150,000 | — | $0 | 0 | SEC↗ |
| Triola Anna Diaz | Chief Commercial Officer | D To issuer | 2022-07-11 | 2022-07-11 | 125,000 | — | $0 | 0 | SEC↗ |
| Wagner Kristie Ann | VP, Principal Fin & Acct Off | D To issuer | 2022-07-11 | 2022-07-11 | 80,500 | — | $0 | 0 | SEC↗ |
| Innoviva Strategic Opportuniti | P Buy | 2022-07-11 | 2022-07-13 | 7,598,814 | $2.20 | $16.72M | 29,270,476 | SEC↗ | |
| Innoviva Strategic Opportuniti | P Buy | 2022-07-08 | 2022-07-13 | 11,671,662 | $2.20 | $25.68M | 21,671,662 | SEC↗ | |
| Altarac David | Chief Medical Officer | U Tender | 2022-07-07 | 2022-07-11 | 17,572 | $2.20 | $38.7K | 0 | SEC↗ |
| Berger Heather A. | Director | U Tender | 2022-07-07 | 2022-07-11 | 22,000 | $2.20 | $48.4K | 0 | SEC↗ |
| HASTINGS DAVID C | Director | U Tender | 2022-07-07 | 2022-07-11 | 22,000 | $2.20 | $48.4K | 0 | SEC↗ |
| Keiley Elizabeth M | General Counsel | U Tender | 2022-07-07 | 2022-07-11 | 17,572 | $2.20 | $38.7K | 0 | SEC↗ |
| Mayer Howard | Director | U Tender | 2022-07-07 | 2022-07-11 | 22,000 | $2.20 | $48.4K | 0 | SEC↗ |
| Meek David D. | Director | U Tender | 2022-07-07 | 2022-07-11 | 22,000 | $2.20 | $48.4K | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | U Tender | 2022-07-07 | 2022-07-11 | 17,092 | $2.20 | $37.6K | 0 | SEC↗ |
| Perros Manoussos | President and CEO | U Tender | 2022-07-07 | 2022-07-11 | 56,072 | $2.20 | $123.4K | 0 | SEC↗ |
| Ronsheim Matthew | Chief of Pharma Sciences & M | U Tender | 2022-07-07 | 2022-07-11 | 17,572 | $2.20 | $38.7K | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | U Tender | 2022-07-07 | 2022-07-11 | 39,596 | $2.20 | $87.1K | 0 | SEC↗ |
| Wagner Kristie Ann | VP, Principal Fin & Acct Off | A Award | 2022-02-24 | 2022-02-25 | 10,000 | — | $0 | 80,500 | SEC↗ |
| Innoviva Strategic Opportuniti | Director, 10% Owner | J Other deriv | 2022-02-18 | 2022-02-23 | 0 | — | $0 | 10,000,000 | SEC↗ |
| Innoviva Strategic Opportuniti | Director, 10% Owner | J Other deriv | 2022-02-18 | 2022-02-23 | 0 | — | $0 | 0 | SEC↗ |
| Triola Anna Diaz | Chief Commercial Officer | A Award | 2022-01-18 | 2022-01-19 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Altarac David | Chief Medical Officer | A Award | 2022-01-18 | 2022-01-19 | 125,000 | — | $0 | 167,572 | SEC↗ |
| HASTINGS DAVID C | Director | A Award | 2022-01-18 | 2022-01-19 | 27,500 | — | $0 | 49,500 | SEC↗ |
| Meek David D. | Director | A Award | 2022-01-18 | 2022-01-19 | 27,500 | — | $0 | 49,500 | SEC↗ |
| Keiley Elizabeth M | General Counsel | A Award | 2022-01-18 | 2022-01-19 | 125,000 | — | $0 | 167,572 | SEC↗ |
| Behanna Heather | Director | A Award | 2022-01-18 | 2022-01-19 | 27,500 | — | $0 | 49,500 | SEC↗ |
| Mayer Howard | Director | A Award | 2022-01-18 | 2022-01-19 | 27,500 | — | $0 | 49,500 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award | 2022-01-18 | 2022-01-19 | 125,000 | — | $0 | 167,092 | SEC↗ |
| Perros Manoussos | See Remarks | A Award | 2022-01-18 | 2022-01-19 | 125,000 | — | $0 | 534,572 | SEC↗ |
| Ronsheim Matthew | See Remarks | A Award | 2022-01-18 | 2022-01-19 | 125,000 | — | $0 | 167,572 | SEC↗ |
| Gutch Michael | See Remarks | A Award | 2022-01-18 | 2022-01-19 | 125,000 | — | $0 | 167,572 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award | 2022-01-18 | 2022-01-19 | 125,000 | — | $0 | 189,596 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | F Tax w/h | 2021-11-02 | 2021-11-03 | 3,669 | $2.94 | $10.8K | 64,596 | SEC↗ |
| Gutch Michael | CFO and Chief Business Offic | F Tax w/h | 2021-11-02 | 2021-11-03 | 3,669 | $2.94 | $10.8K | 42,572 | SEC↗ |
| Perros Manoussos | President and CEO | F Tax w/h | 2021-11-02 | 2021-11-03 | 11,704 | $2.94 | $34.4K | 135,822 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | F Tax w/h | 2021-11-02 | 2021-11-03 | 3,907 | $2.94 | $11.5K | 42,092 | SEC↗ |
| Altarac David | Chief Medical Officer | F Tax w/h | 2021-11-02 | 2021-11-03 | 3,669 | $2.94 | $10.8K | 42,572 | SEC↗ |
| Keiley Elizabeth M | General Counsel | F Tax w/h | 2021-11-02 | 2021-11-03 | 3,669 | $2.94 | $10.8K | 42,572 | SEC↗ |
| Ronsheim Matthew | Chief, Pharma Sciences & MFG | F Tax w/h | 2021-11-02 | 2021-11-03 | 3,669 | $2.94 | $10.8K | 42,572 | SEC↗ |
| Ronsheim Matthew | See Remarks | A Award | 2021-10-19 | 2021-10-20 | 25,000 | — | $0 | 50,000 | SEC↗ |
| Ronsheim Matthew | See Remarks | S Sale | 2021-10-19 | 2021-10-20 | 3,759 | $3.19 | $12.0K | 46,241 | SEC↗ |
| Altarac David | Chief Medical Officer | A Award | 2021-10-19 | 2021-10-20 | 25,000 | — | $0 | 50,000 | SEC↗ |
| Altarac David | Chief Medical Officer | S Sale | 2021-10-19 | 2021-10-20 | 3,759 | $3.19 | $12.0K | 46,241 | SEC↗ |
| Keiley Elizabeth M | General Counsel | A Award | 2021-10-19 | 2021-10-20 | 25,000 | — | $0 | 50,000 | SEC↗ |
| Keiley Elizabeth M | General Counsel | S Sale | 2021-10-19 | 2021-10-20 | 3,759 | $3.19 | $12.0K | 46,241 | SEC↗ |
| Gutch Michael | See Remarks | S Sale | 2021-10-19 | 2021-10-20 | 3,759 | $3.19 | $12.0K | 46,241 | SEC↗ |
| Gutch Michael | See Remarks | A Award | 2021-10-19 | 2021-10-20 | 25,000 | — | $0 | 50,000 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award | 2021-10-19 | 2021-10-20 | 25,000 | — | $0 | 50,000 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | S Sale | 2021-10-19 | 2021-10-20 | 4,001 | $3.19 | $12.8K | 45,999 | SEC↗ |
| Perros Manoussos | See Remarks | A Award | 2021-10-19 | 2021-10-20 | 79,750 | — | $0 | 159,500 | SEC↗ |
| Perros Manoussos | See Remarks | S Sale | 2021-10-19 | 2021-10-20 | 11,974 | $3.19 | $38.2K | 147,526 | SEC↗ |
| Triola Anna Diaz | Chief Commercial Officer | A Award deriv | 2021-07-19 | 2021-07-20 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Keiley Elizabeth M | General Counsel | D To issuer deriv | 2021-07-16 | 2022-02-15 | 25,000 | — | $0 | 0 | SEC↗ |
| Keiley Elizabeth M | General Counsel | A Award deriv | 2021-07-16 | 2022-02-15 | 20,833 | — | $0 | 20,833 | SEC↗ |
| HASTINGS DAVID C | Director | D To issuer deriv | 2021-07-16 | 2022-02-15 | 7,500 | — | $0 | 0 | SEC↗ |
| HASTINGS DAVID C | Director | A Award deriv | 2021-07-16 | 2022-02-15 | 11,538 | — | $0 | 11,538 | SEC↗ |
| HASTINGS DAVID C | Director | A Award deriv | 2021-07-16 | 2022-02-15 | 5,769 | — | $0 | 5,769 | SEC↗ |
| HASTINGS DAVID C | Director | D To issuer deriv | 2021-07-16 | 2022-02-15 | 12,060 | — | $0 | 0 | SEC↗ |
| HASTINGS DAVID C | Director | A Award deriv | 2021-07-16 | 2022-02-15 | 9,276 | — | $0 | 9,276 | SEC↗ |
| HASTINGS DAVID C | Director | D To issuer deriv | 2021-07-16 | 2022-02-15 | 15,000 | — | $0 | 0 | SEC↗ |
| Altarac David | Chief Medical Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 92 | — | $0 | 92,307 | SEC↗ |
| Altarac David | Chief Medical Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 120,000 | — | $0 | 0 | SEC↗ |
| Behanna Heather | Director | D To issuer deriv | 2021-07-16 | 2022-02-15 | 15,000 | — | $0 | 0 | SEC↗ |
| Behanna Heather | Director | A Award deriv | 2021-07-16 | 2022-02-15 | 11,538 | — | $0 | 11,538 | SEC↗ |
| Behanna Heather | Director | D To issuer deriv | 2021-07-16 | 2022-02-15 | 7,500 | — | $0 | 0 | SEC↗ |
| Behanna Heather | Director | A Award deriv | 2021-07-16 | 2022-02-15 | 5,769 | — | $0 | 5,769 | SEC↗ |
| Meek David D. | Director | A Award deriv | 2021-07-16 | 2022-02-15 | 5,769 | — | $0 | 5,769 | SEC↗ |
| Meek David D. | Director | D To issuer deriv | 2021-07-16 | 2022-02-15 | 7,500 | — | $0 | 0 | SEC↗ |
| Meek David D. | Director | A Award deriv | 2021-07-16 | 2022-02-15 | 11,538 | — | $0 | 11,538 | SEC↗ |
| Meek David D. | Director | D To issuer deriv | 2021-07-16 | 2022-02-15 | 15,000 | — | $0 | 0 | SEC↗ |
| Mayer Howard | Director | A Award deriv | 2021-07-16 | 2022-02-15 | 12,500 | — | $0 | 12,500 | SEC↗ |
| Mayer Howard | Director | D To issuer deriv | 2021-07-16 | 2022-02-15 | 15,000 | — | $0 | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 56,500 | — | $0 | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 4,035 | — | $0 | 4,035 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 43,460 | — | $0 | 43,460 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 7,265 | — | $0 | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 12,993 | — | $0 | 12,993 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 16,892 | — | $0 | 0 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 15,210 | — | $0 | 15,210 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 22,816 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | A Award deriv | 2021-07-16 | 2022-02-15 | 95,000 | — | $0 | 95,000 | SEC↗ |
| Perros Manoussos | President and CEO | D To issuer deriv | 2021-07-16 | 2022-02-15 | 87,462 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | A Award deriv | 2021-07-16 | 2022-02-15 | 58,307 | — | $0 | 58,307 | SEC↗ |
| Perros Manoussos | President and CEO | D To issuer deriv | 2021-07-16 | 2022-02-15 | 166,623 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | A Award deriv | 2021-07-16 | 2022-02-15 | 128,531 | — | $0 | 128,531 | SEC↗ |
| Perros Manoussos | President and CEO | D To issuer deriv | 2021-07-16 | 2022-02-15 | 79,698 | — | $0 | 0 | SEC↗ |
| Perros Manoussos | President and CEO | A Award deriv | 2021-07-16 | 2022-02-15 | 44,276 | — | $0 | 44,276 | SEC↗ |
| Perros Manoussos | President and CEO | D To issuer deriv | 2021-07-16 | 2022-02-15 | 123,500 | — | $0 | 0 | SEC↗ |
| Ronsheim Matthew | See Remarks | A Award deriv | 2021-07-16 | 2022-02-15 | 33,333 | — | $0 | 33,333 | SEC↗ |
| Ronsheim Matthew | See Remarks | D To issuer deriv | 2021-07-16 | 2022-02-15 | 40,000 | — | $0 | 0 | SEC↗ |
| Gutch Michael | See Remarks | D To issuer deriv | 2021-07-16 | 2022-02-15 | 15,956 | — | $0 | 0 | SEC↗ |
| Gutch Michael | See Remarks | A Award deriv | 2021-07-16 | 2022-02-15 | 8,863 | — | $0 | 8,863 | SEC↗ |
| Gutch Michael | See Remarks | D To issuer deriv | 2021-07-16 | 2022-02-15 | 30,006 | — | $0 | 0 | SEC↗ |
| Gutch Michael | See Remarks | A Award deriv | 2021-07-16 | 2022-02-15 | 43,460 | — | $0 | 43,460 | SEC↗ |
| Gutch Michael | See Remarks | D To issuer deriv | 2021-07-16 | 2022-02-15 | 56,500 | — | $0 | 0 | SEC↗ |
| Gutch Michael | See Remarks | A Award deriv | 2021-07-16 | 2022-02-15 | 23,081 | — | $0 | 23,081 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 12,024 | — | $0 | 12,024 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 56,500 | — | $0 | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 28,006 | — | $0 | 28,006 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 50,411 | — | $0 | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 43,460 | — | $0 | 43,460 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 15,632 | — | $0 | 0 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award deriv | 2021-07-16 | 2022-02-15 | 15,210 | — | $0 | 15,210 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | D To issuer deriv | 2021-07-16 | 2022-02-15 | 22,816 | — | $0 | 0 | SEC↗ |
| Innoviva Strategic Opportuniti | 10% Owner | P Buy deriv | 2021-06-11 | 2021-06-11 | 6,268,975 | $2.00 | $12.54M | 10,000,000 | SEC↗ |
| Innoviva Strategic Opportuniti | 10% Owner | P Buy | 2021-06-11 | 2021-06-11 | 6,268,975 | $2.00 | $12.54M | 10,000,000 | SEC↗ |
| Innoviva, Inc. | 10% Owner | P Buy deriv | 2021-05-03 | 2021-05-20 | 3,731,025 | $2.00 | $7.46M | 3,731,025 | SEC↗ |
| Innoviva, Inc. | 10% Owner | P Buy | 2021-05-03 | 2021-05-20 | 3,731,025 | $2.00 | $7.46M | 3,731,025 | SEC↗ |
| HASTINGS DAVID C | Director | A Award | 2021-04-01 | 2021-04-02 | 22,000 | — | $0 | 22,000 | SEC↗ |
| Meek David D. | Director | A Award | 2021-04-01 | 2021-04-02 | 22,000 | — | $0 | 22,000 | SEC↗ |
| Behanna Heather | Director | A Award | 2021-04-01 | 2021-04-02 | 22,000 | — | $0 | 22,000 | SEC↗ |
| Mayer Howard | Director | A Award | 2021-04-01 | 2021-04-02 | 22,000 | — | $0 | 22,000 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award | 2021-01-15 | 2021-01-19 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Altarac David | Chief Medical Officer | A Award | 2021-01-15 | 2021-01-19 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Keiley Elizabeth M | General Counsel | A Award | 2021-01-15 | 2021-01-19 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Perros Manoussos | President & CEO | A Award | 2021-01-15 | 2021-01-19 | 79,750 | — | $0 | 79,750 | SEC↗ |
| Ronsheim Matthew | See Remarks | A Award | 2021-01-15 | 2021-01-19 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Gutch Michael | CFO & CBO | A Award | 2021-01-15 | 2021-01-19 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award | 2021-01-15 | 2021-01-19 | 25,000 | — | $0 | 47,024 | SEC↗ |
| Innoviva, Inc. | 10% Owner | P Buy deriv | 2020-09-01 | 2020-09-01 | 4,672,897 | $2.68 | $12.52M | 18,672,897 | SEC↗ |
| Innoviva, Inc. | 10% Owner | P Buy | 2020-09-01 | 2020-09-01 | 4,672,897 | $2.68 | $12.52M | 18,672,897 | SEC↗ |
| Innoviva, Inc. | 10% Owner | P Buy deriv | 2020-06-11 | 2020-06-12 | 12,677,490 | $2.50 | $31.69M | 14,000,000 | SEC↗ |
| Innoviva, Inc. | 10% Owner | P Buy | 2020-06-11 | 2020-06-12 | 12,677,490 | $2.50 | $31.69M | 14,000,000 | SEC↗ |
| Mayer Howard | Director | A Award deriv | 2020-06-10 | 2020-10-06 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Behanna Heather | Director | A Award deriv | 2020-06-10 | 2020-10-06 | 11,000 | — | $0 | 11,000 | SEC↗ |
| HASTINGS DAVID C | Director | A Award deriv | 2020-06-10 | 2020-10-06 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Meek David D. | Director | A Award deriv | 2020-06-10 | 2020-10-06 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award deriv | 2020-01-23 | 2020-01-27 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award deriv | 2020-01-23 | 2020-01-27 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Gutch Michael | Chief Fin. and Bus. Officer | A Award deriv | 2020-01-23 | 2020-01-27 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Keiley Elizabeth M | General Counsel | A Award deriv | 2020-01-23 | 2020-01-27 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Kimble Eric Wilson | Chief Commercial Officer | A Award deriv | 2020-01-23 | 2020-01-27 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Perros Manoussos | President and CEO | A Award deriv | 2020-01-23 | 2020-01-27 | 145,000 | — | $0 | 145,000 | SEC↗ |
| Altarac David | Chief Medical Officer | A Award deriv | 2020-01-23 | 2020-01-27 | 50,000 | — | $0 | 50,000 | SEC↗ |
| FHM LIFE SCIENCES VIII, L.P. | 10% Owner | S Sale | 2020-01-09 | 2020-01-13 | 50,000 | $5.00 | $250.0K | 1,299,953 | SEC↗ |
| Altarac David | Chief Medical Officer | A Award deriv | 2019-11-04 | 2019-11-06 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Mayer Howard | Director | A Award deriv | 2019-08-05 | 2019-08-06 | 15,000 | — | $0 | 15,000 | SEC↗ |
| GALAKATOS NICHOLAS | Director | A Award deriv | 2019-06-19 | 2019-06-21 | 7,500 | — | $0 | 7,500 | SEC↗ |
| Preston Heather | Director | A Award deriv | 2019-06-19 | 2019-06-21 | 7,500 | — | $0 | 7,500 | SEC↗ |
| Behanna Heather | Director | A Award deriv | 2019-06-19 | 2019-06-21 | 7,500 | — | $0 | 7,500 | SEC↗ |
| Norden Gregory | Director | A Award deriv | 2019-06-19 | 2019-06-21 | 7,500 | — | $0 | 7,500 | SEC↗ |
| HASTINGS DAVID C | Director | A Award deriv | 2019-06-19 | 2019-06-21 | 7,500 | — | $0 | 7,500 | SEC↗ |
| Meek David D. | Director | A Award deriv | 2019-06-19 | 2019-06-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Meek David D. | Director | A Award deriv | 2019-06-19 | 2019-06-21 | 7,500 | — | $0 | 7,500 | SEC↗ |
| Behanna Heather | Director | A Award deriv | 2019-01-18 | 2019-01-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | A Award deriv | 2019-01-18 | 2019-01-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Gutch Michael | CFO and Chief Business Offic | A Award deriv | 2019-01-18 | 2019-01-22 | 56,500 | — | $0 | 56,500 | SEC↗ |
| HASTINGS DAVID C | Director | A Award deriv | 2019-01-18 | 2019-01-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Isaacs Robin | Chief Medical Officer | A Award deriv | 2019-01-18 | 2019-01-22 | 56,500 | — | $0 | 56,500 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award deriv | 2019-01-18 | 2019-01-22 | 56,500 | — | $0 | 56,500 | SEC↗ |
| Norden Gregory | Director | A Award deriv | 2019-01-18 | 2019-01-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Perros Manoussos | President and CEO | A Award deriv | 2019-01-18 | 2019-01-22 | 123,500 | — | $0 | 123,500 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award deriv | 2019-01-18 | 2019-01-22 | 56,500 | — | $0 | 56,500 | SEC↗ |
| Topper James N | Director, 10% Owner | A Award deriv | 2019-01-18 | 2019-01-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | M Exercise deriv | 2018-12-21 | 2018-12-26 | 10,236 | — | $0 | 24,858 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | M Exercise deriv | 2018-12-21 | 2018-12-26 | 11,788 | — | $0 | 6,465 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | M Exercise | 2018-12-21 | 2018-12-26 | 10,236 | $3.11 | $31.8K | 22,024 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | M Exercise | 2018-12-21 | 2018-12-26 | 11,788 | $3.74 | $44.1K | 11,788 | SEC↗ |
| Novo Holdings A/S | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-01 | 7,000,000 | — | $0 | 0 | SEC↗ |
| Novo Holdings A/S | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-01 | 14,237,288 | — | $0 | 0 | SEC↗ |
| BONDERMAN DAVID | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 15,254,237 | — | $0 | 0 | SEC↗ |
| ASTRAZENECA PLC | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 33,499,900 | — | $0 | 0 | SEC↗ |
| Clarus Ventures III, LLC | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 6,702,213 | — | $0 | 0 | SEC↗ |
| Clarus Ventures III, LLC | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 8,552,024 | — | $0 | 0 | SEC↗ |
| Clarus Ventures III, LLC | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 7,500,000 | — | $0 | 0 | SEC↗ |
| Heron Patrick J | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 7,000,000 | — | $0 | 0 | SEC↗ |
| Heron Patrick J | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 5,212,833 | — | $0 | 0 | SEC↗ |
| Heron Patrick J | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 6,651,574 | — | $0 | 0 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 6,702,213 | — | $0 | 0 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 8,552,024 | — | $0 | 0 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 7,500,000 | — | $0 | 0 | SEC↗ |
| Pivotal bioVenture Partners Fu | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 9,502,249 | — | $0 | 0 | SEC↗ |
| Pivotal bioVenture Partners Fu | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 7,446,904 | — | $0 | 0 | SEC↗ |
| Preston Heather | Director, 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 9,502,249 | — | $0 | 0 | SEC↗ |
| Preston Heather | Director, 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 7,446,904 | — | $0 | 0 | SEC↗ |
| POWELL MICHAEL | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 7,446,904 | — | $0 | 0 | SEC↗ |
| POWELL MICHAEL | 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 9,502,249 | — | $0 | 0 | SEC↗ |
| Topper James N | Director, 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 6,651,574 | — | $0 | 0 | SEC↗ |
| Topper James N | Director, 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 5,212,833 | — | $0 | 0 | SEC↗ |
| Topper James N | Director, 10% Owner | C Conversion deriv | 2018-09-28 | 2018-10-02 | 7,000,000 | — | $0 | 0 | SEC↗ |
| Novo Holdings A/S | 10% Owner | P Buy | 2018-09-28 | 2018-10-01 | 1,089,835 | $15.00 | $16.35M | 2,181,843 | SEC↗ |
| Novo Holdings A/S | 10% Owner | C Conversion | 2018-09-28 | 2018-10-01 | 1,092,008 | — | $0 | 1,092,008 | SEC↗ |
| BONDERMAN DAVID | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 735,924 | — | $0 | 735,924 | SEC↗ |
| BONDERMAN DAVID | 10% Owner | J Other | 2018-09-28 | 2018-10-02 | 22,285 | — | $0 | 758,209 | SEC↗ |
| BONDERMAN DAVID | 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 262,539 | $15.00 | $3.94M | 1,020,748 | SEC↗ |
| ASTRAZENECA PLC | 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 246,666 | $15.00 | $3.70M | 2,164,855 | SEC↗ |
| ASTRAZENECA PLC | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 1,918,185 | — | $0 | 1,918,189 | SEC↗ |
| Clarus Ventures III, LLC | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 361,829 | — | $0 | 361,829 | SEC↗ |
| Clarus Ventures III, LLC | 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 453,395 | $15.00 | $6.80M | 1,623,405 | SEC↗ |
| Clarus Ventures III, LLC | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 412,583 | — | $0 | 1,170,010 | SEC↗ |
| Clarus Ventures III, LLC | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 323,341 | — | $0 | 685,170 | SEC↗ |
| Heron Patrick J | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 320,898 | — | $0 | 974,066 | SEC↗ |
| Heron Patrick J | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 251,487 | — | $0 | 589,194 | SEC↗ |
| Heron Patrick J | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 337,707 | — | $0 | 337,707 | SEC↗ |
| Heron Patrick J | 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 375,887 | $15.00 | $5.64M | 1,349,953 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 323,341 | — | $0 | 685,170 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 361,829 | — | $0 | 361,829 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 453,395 | $15.00 | $6.80M | 1,623,405 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 412,583 | — | $0 | 1,170,010 | SEC↗ |
| Pivotal bioVenture Partners Fu | 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 337,724 | $15.00 | $5.07M | 1,180,178 | SEC↗ |
| Pivotal bioVenture Partners Fu | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 458,425 | — | $0 | 842,454 | SEC↗ |
| Pivotal bioVenture Partners Fu | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 359,267 | — | $0 | 359,267 | SEC↗ |
| Preston Heather | Director, 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 458,425 | — | $0 | 842,454 | SEC↗ |
| Preston Heather | Director, 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 337,724 | $15.00 | $5.07M | 1,180,178 | SEC↗ |
| Preston Heather | Director, 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 359,267 | — | $0 | 359,267 | SEC↗ |
| POWELL MICHAEL | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 359,267 | — | $0 | 359,267 | SEC↗ |
| POWELL MICHAEL | 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 337,724 | $15.00 | $5.07M | 1,180,178 | SEC↗ |
| POWELL MICHAEL | 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 458,425 | — | $0 | 842,454 | SEC↗ |
| Topper James N | Director, 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 337,707 | — | $0 | 337,707 | SEC↗ |
| Topper James N | Director, 10% Owner | P Buy | 2018-09-28 | 2018-10-02 | 375,887 | $15.00 | $5.64M | 1,349,953 | SEC↗ |
| Topper James N | Director, 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 320,898 | — | $0 | 974,066 | SEC↗ |
| Topper James N | Director, 10% Owner | C Conversion | 2018-09-28 | 2018-10-02 | 251,487 | — | $0 | 589,194 | SEC↗ |
| Gutch Michael | CFO and Chief Business Offic | A Award deriv | 2018-09-25 | 2018-09-27 | 15,956 | — | $0 | 15,956 | SEC↗ |
| Isaacs Robin | Chief Medical Officer | A Award deriv | 2018-09-25 | 2018-09-27 | 32,116 | — | $0 | 32,116 | SEC↗ |
| Mueller John Patrick | Chief Development Officer | A Award deriv | 2018-09-25 | 2018-09-27 | 7,265 | — | $0 | 7,265 | SEC↗ |
| Tommasi Ruben | Chief Scientific Officer | A Award deriv | 2018-09-25 | 2018-09-27 | 50,411 | — | $0 | 50,411 | SEC↗ |
| Perros Manoussos | President and CEO | A Award deriv | 2018-09-25 | 2018-09-27 | 79,698 | — | $0 | 79,698 | SEC↗ |